RCMI Coordinating Center (RCMI CC) Header Logo

Jaydutt V Vadgama, PhD

TitleProfessor
Faculty RankProfessor
InstitutionCharles R. Drew University of Medicine and Science
DepartmentInternal Medicine
Address1731 E. 120th Street, Hawkins Building
1731 E. 120th Street, Hawkins Building
Los Angeles CA 90059
Phone3235639397
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of East London, London, EnglandB.Sc1975Biochemistry/Psychiology
    University of London, London, EnglandPh.D.1981Biochemistry
    University of Michigan, Ann Arbor, MIPostdoctoral FellowshipBiological Chemistry

    Collapse Overview 
    Collapse overview
    Dr. Vadgama is the Vice President for Research and Health Affairs at Charles R. Drew University of Medicine and Science (CDU). He is a full Professor of Medicine at CDU and at the UCLA David Geffen School of Medicine in the Department(s) of Internal Medicine. Dr. Vadgama has provided significant leadership in growing and sustaining research at CDU over the last two decades. Dr. Vadgama has led several additional administrative responsibilities that include Chair of the Institutional Space Committee, Chair of the PhD Planning Committee, establishing the Intellectual Property/Patent Committee at CDU, Institutional Official for IACUC and chairing several Task Force committees.

    Leadership Experience: Dr. Vadgama continues to serve as Division Chief, Center Director, Vice President, member of the President’s Executive Team and the Provost’s Team in addition to several additional executive roles. He has over 30 years of direct experience in Academia and Research with a strong understanding of the processes, policies and procedures necessary to attain academic excellence. He continues to provide significant support and leadership to students, faculty, the Academic Senate, division chiefs, department chairs, deans, provosts and the University president on matters relevant to research, academic processes, challenges and growth. He continues to work with faculty, students and staff to strengthen clinical, basic and translational research/programs, integrate them with academic programs across campus, and develop strong partnerships with UCLA, Cedars and other institutions. At the request of the University president and deans, he has represented the University at several national forums on cancer and health disparities and he serves in an advisory capacity to the president and the Executive Team for directing research initiatives at CDU in partnership with other institutions.

    Strength in Diversity: Dr. Vadgama has over 20 years of experience in working at Historically Black College and University (HBCU) and Hispanic Serving institution (HSI). In 1992/3, he joined Charles R. Drew University of Medicine and Science as Director of Laboratory Research and Development to develop research infrastructure in Biomedical Sciences that supported underrepresented and underserved undergraduate students, graduate students, medical residents, clinical fellows, postdoctoral fellows, and faculty. In addition, during these last 21 years and prior, he has had extensive experience working with underrepresented and under resourced communities in South Los Angeles and neighboring communities. Dr. Vadgama states: “It continues to be an honor and privilege to be able to make differences in the day to day lives of our students, faculty, staff, and community partners.”

    Translational Cancer Research Experience: Dr. Vadgama has extensive experience in conducting oncology research that integrates clinical, basic and community-partnered research. The outcome of these efforts has resulted in the development of translational cancer research at CDU. His research team is providing significant leadership in understanding the role of comorbidities such Diabetes and Hypertension in the risk and prognosis for cancer diagnosis and treatment. His group has identified that Obesity contributes significantly to the risk for cancer development and poor clinical outcome. The CDU/UCLA Cancer Center Partnership was recently refunded for over $12.6M (2015-2020) by the National Cancer Institute (U54CA143931) to enhance cancer disparities research at CDU and support programs in developing novel research, sustaining a biomarker identification repository, formal training programs for students, fellows, and faculty, as well as community engagement activities, and clinical research studies. In addition, Dr. Vadgama serves as PI for the Accelerating Excellence in Translational Science Center (U54MD007598), recently funded for $18.76M (2019-2025). The overall purpose of AXIS is to better position CDU for conducting clinical and translational research, especially research focused on health disparities.

    Other Professional Experience: Dr. Vadgama serves as reviewer for grants submitted to the NIH, DOD, VHA, and EPSRC. He is Editor-In-Chief of IJBS, Clinics in Oncology Journal and serves on the editorial board of 14 journals and an ad-hoc reviewer for 30 peer-reviewed journals. Dr. Vadgama has participated at national and international cancer meetings as chair, co-chair, invited honorary and keynote speaker. In addition, he has served on several community-partnered panels and conferences and honored with a Distinguished Achievement Award for Research and Community Partnership award from the Watts Area Ministers (WAM).

    Teaching and Training Experience: Dr. Vadgama has extensive experience in training students, residents and fellows in basic, clinical and translational cancer research. His training programs have been funded from the NIH since 2004 and he serves as mentor and reviewer for several training programs including the CTSI and Susan G. Komen Foundation. To date, Dr. Vadgama has mentored 59 postdoctoral and clinical fellows, 34 graduate students, 16 medical students (mostly underrepresented), 149 undergraduate students across the nation, and 35 high school students. Dr. Vadgama continues to serve as a mentor for several funded early stage investigators at CDU and the UCLA School of Medicine. In addition, he mentors several underrepresented trainees from schools such as CDU, UCLA, UCI, UCR, CSUDH, USC and others.

    Collapse Research 
    Collapse research activities and funding
    R29DK039147     (VADGAMA, JAYDUTT V)Aug 1, 1987 - Nov 30, 1992
    NIH
    REGULATION OF AMINO ACID TRANSPORT IN ERYTHROID CELLS
    Role: Principal Investigator

    U56CA101599     (VADGAMA, JAYDUTT V)Sep 5, 2003 - Jul 31, 2010
    NIH
    Drew/UCLA Cancer Partnership Program
    Role: Principal Investigator

    R25DK067015     (VADGAMA, JAYDUTT V)Sep 30, 2003 - Jul 31, 2009
    NIH
    Charles R. Drew Student Scholar Program
    Role: Principal Investigator

    U54MD007598     (VADGAMA, JAYDUTT V)Sep 28, 2009 - Feb 29, 2024
    NIH
    Accelerating Excellence in Translational Science (AXIS)
    Role: Principal Investigator

    U54CA143931     (VADGAMA, JAYDUTT V)Sep 29, 2009 - Aug 31, 2021
    NIH
    CDU-UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. He Q, Hao Q, Wu Y, Vadgama JV, Jiang Y. CircRAD54L2 promotes triple-negative breast cancer progression by regulating the miR-888 family/PDK1 axis. Life Sci. 2022 Nov 02; 121128. PMID: 36334805.
      Citations:    
    2. Sterling C, Márquez-Garbán D, Vadgama JV, Pietras RJ. Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. Cancers (Basel). 2022 Oct 21; 14(20). PMID: 36291938.
      Citations:    
    3. Hao Q, Wu Y, Vadgama JV, Wang P. Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies. Biomolecules. 2022 Sep 16; 12(9). PMID: 36139145.
      Citations:    
    4. Tian S, Su R, Wu K, Zhou X, Vadgama JV, Wu Y. Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells. J Pers Med. 2022 Aug 16; 12(8). PMID: 36013267.
      Citations:    
    5. Liu D, Hao Q, Li J, Li Q, Wang K, Geng Q, Wu Y, Vadgama JV, Wu Y. ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients. Cancer Commun (Lond). 2022 Jul; 42(7):663-667. PMID: 35486908.
      Citations:    
    6. Yang S, Jackson C, Karapetyan E, Dutta P, Kermah D, Wu Y, Wu Y, Schloss J, Vadgama JV. Roles of Protein Disulfide Isomerase in Breast Cancer. Cancers (Basel). 2022 Jan 31; 14(3). PMID: 35159012.
      Citations:    
    7. Hao Q, Wu Y, Wu Y, Wang P, Vadgama JV. Tumor-Derived Exosomes in Tumor-Induced Immune Suppression. Int J Mol Sci. 2022 Jan 27; 23(3). PMID: 35163380.
      Citations:    
    8. Wu Y, Dutta P, Clayton S, McCloud A, Vadgama JV. Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women. J Clin Med. 2022 Jan 06; 11(2). PMID: 35053979.
      Citations:    
    9. Deng W, Hao Q, Vadgama J, Wu Y. Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer. J Cancer Sci Clin Ther. 2021 Mar 18; 5(1):134-153. PMID: 34950877.
      Citations:    
    10. Liu D, Vadgama J, Wu Y. Basal-like breast cancer with low TGFß and high TNFa pathway activity is rich in activated memory CD4 T cells and has a good prognosis. Int J Biol Sci. 2021; 17(3):670-682. PMID: 33767579.
      Citations: 6     Fields:    Translation:HumansCells
    11. DeAngelo C, Tarasiewicz MB, Strother A, Taggart H, Gray C, Shanahan M, Glowacki C, Khandalavala J, Talaska E, Kinnan A, Coté JJ, Edwards AP, Harper-Harrison G, Casey MJ, Hirai TL, Schultz S, Stines L, Vora R, Boudreau D, Burgart J, Shama M, Watson T, Strasheim L, Thompson R, Lawlor R, Joyce K, Magnuson CM, Driano J, Elger B, Lentino A, Driscoll M, Tidwell E, Sharma A, Walker SR, Jones G, Sharma P, Stessman H, Wu Y, Vadgama J, Chase D, Conrad L, Reddy ST, Farias-Eisner R. Endometriosis: A Malignant Fingerprint. J Cancer Res Ther Oncol. 2020 Apr; 8(2). PMID: 33644256.
      Citations:    
    12. Hao Q, Wang P, Dutta P, Chung S, Li Q, Wang K, Li J, Cao W, Deng W, Geng Q, Schrode K, Shaheen M, Wu K, Zhu D, Chen QH, Chen G, Elshimali Y, Vadgama J, Wu Y. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052. PMID: 33311440.
      Citations: 3     Fields:    Translation:HumansCells
    13. Jimenez T, Friedman T, Vadgama J, Singh V, Tucker A, Collazo J, Sinha S, Hikim AS, Singh R, Pervin S. Nicotine Synergizes with High-Fat Diet to Induce an Anti-Inflammatory Microenvironment to Promote Breast Tumor Growth. Mediators Inflamm. 2020; 2020:5239419. PMID: 33414685.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    14. Wu Y, Sarkissyan M, Ogah O, Kim J, Vadgama JV. Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers. Cancers (Basel). 2020 Jul 16; 12(7). PMID: 32708561.
      Citations:    
    15. Hao Q, Vadgama JV, Wang P. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020 05 29; 18(1):82. PMID: 32471499.
      Citations: 44     Fields:    Translation:HumansAnimals
    16. Dillard C, Kiyohara M, Mah V, McDermott SP, Bazzoun D, Tsui J, Chan AM, Haddad G, Pellegrini M, Chang YL, Elshimali Y, Wu Y, Vadgama JV, Kim SR, Goodglick L, Law SM, Patel DD, Dhawan P, O'Brien NA, Gordon LK, Braun J, Lazar G, Wicha MS, Wadehra M. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells. Mol Cancer Ther. 2020 08; 19(8):1682-1695. PMID: 32451329.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    17. Dutta P, Paico K, Gomez G, Wu Y, Vadgama JV. Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer. Cancers (Basel). 2020 May 21; 12(5). PMID: 32455851.
      Citations:    
    18. Keung MY, Wu Y, Badar F, Vadgama JV. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. J Clin Med. 2020 Mar 30; 9(4). PMID: 32235451.
      Citations:    
    19. Hao Q, Diaz T, Verduzco ADR, Magyar CE, Zhong J, Elshimali Y, Rettig MB, Henning SM, Vadgama JV, Wang P. Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor. Sci Rep. 2020 Jan 29; 10(1):1403. PMID: 31996731.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    20. Deng W, Li J, Dorrah K, Jimenez-Tapia D, Arriaga B, Hao Q, Cao W, Gao Z, Vadgama J, Wu Y. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 May; 125:109956. PMID: 32006900.
      Citations: 7     Fields:    Translation:Cells
    21. Su F, Gm A, Palgunachari MN, White CR, Stessman H, Wu Y, Vadgama J, Pietras R, Nguyen D, Reddy ST, Farias-Eisner R. Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. J Cancer Res Ther Oncol. 2020; 8(1). PMID: 32462055.
      Citations:    
    22. Li Q, Hao Q, Cao W, Li J, Wu K, Elshimali Y, Zhu D, Chen QH, Chen G, Pollack JR, Vadgama J, Wu Y. PP2Cd inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer. Sci Adv. 2019 10; 5(10):eaaw8417. PMID: 31663018.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    23. Chung SS, Dutta P, Chard N, Wu Y, Chen QH, Chen G, Vadgama J. A novel curcumin analog inhibits canonical and non-canonical functions of telomerase through STAT3 and NF-?B inactivation in colorectal cancer cells. Oncotarget. 2019 Jul 16; 10(44):4516-4531. PMID: 31360301.
      Citations: 11     Fields:    
    24. Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med. 2019 Mar 30; 8(4). PMID: 30934991.
      Citations:    
    25. Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep. 2019 03 26; 9(1):5141. PMID: 30914750.
      Citations: 4     Fields:    Translation:HumansCells
    26. Kaufman M, Cruz A, Thompson J, Reddy S, Bansal N, Cohen JG, Wu Y, Vadgama J, Farias-Eisner R. A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds. J Cancer Metastasis Treat. 2019; 5. PMID: 31236478.
      Citations:    
    27. Ofili EO, Tchounwou PB, Fernandez-Repollet E, Yanagihara R, Akintobi TH, Lee JE, Malouhi M, Garner ST, Hayes TT, Baker AR, Dent AL, Abdelrahim M, Rollins L, Chang SP, Sy A, Hernandez BY, Bullard PL, Noel RJ, Shiramizu B, Hedges JR, Berry MJ, Bond VC, Lima MF, Mokuau N, Kirken RA, Cruz-Correa M, Sarpong DF, Vadgama J, Yates C, Kahn SA, Soliman KF, Perry G, Pezzano M, Luciano CA, Barnett ME, Oyekan A, Kumar D, Norris KC. The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research. Ethn Dis. 2019; 29(Suppl 1):135-144. PMID: 30906162.
      Citations: 6     Fields:    Translation:Humans
    28. Cao W, Li J, Hao Q, Vadgama JV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 02 21; 21(1):29. PMID: 30791936.
      Citations: 24     Fields:    Translation:HumansCells
    29. Nava M, Dutta P, Zemke NR, Farias-Eisner R, Vadgama JV, Wu Y. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. BMC Med Genomics. 2019 02 08; 12(1):32. PMID: 30736768.
      Citations: 3     Fields:    Translation:HumansCells
    30. Li J, Hao Q, Cao W, Vadgama JV, Wu Y. Celecoxib in breast cancer prevention and therapy. Cancer Manag Res. 2018; 10:4653-4667. PMID: 30464589.
      Citations:    
    31. Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018 Sep 21; 9(74):33912-33930. PMID: 30338035.
      Citations: 22     Fields:    
    32. Chung SS, Dutta P, Austin D, Wang P, Awad A, Vadgama JV. Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget. 2018 Aug 31; 9(68):32943-32957. PMID: 30250641.
      Citations: 15     Fields:    
    33. Wu K, Yu X, Huang Z, Zhu D, Yi X, Wu YL, Hao Q, Kemp KT, Elshimali Y, Iyer R, Nguyen KT, Zheng S, Chen G, Chen QH, Wang G, Vadgama JV, Wu Y. Targeting of PP2Cd By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo. Antioxid Redox Signal. 2019 06 10; 30(17):1983-1998. PMID: 29808718.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    34. Dutta P, Sarkissyan M, Paico K, Wu Y, Vadgama JV. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 2018 Aug; 170(3):477-486. PMID: 29594759.
      Citations: 38     Fields:    Translation:HumansCells
    35. Elshimali YI, Wu Y, Khaddour H, Wu Y, Gradinaru D, Sukhija H, Chung SS, Vadgama JV. Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol. 2018; 1(2). PMID: 29932172.
      Citations:    
    36. Petersen SS, Sarkissyan M, Wu Y, Clayton S, Vadgama JV. Time to Clinical Follow-up after Abnormal Mammogram among African American and Hispanic Women. J Health Care Poor Underserved. 2018; 29(1):448-462. PMID: 29503311.
      Citations: 1     Fields:    Translation:Humans
    37. Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11). PMID: 29099049.
      Citations: 3     Fields:    Translation:HumansCells
    38. Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV. Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. Cancers (Basel). 2017 Oct 24; 9(10). PMID: 29064397.
      Citations:    
    39. Chung SS, Wu Y, Okobi Q, Adekoya D, Atefi M, Clarke O, Dutta P, Vadgama JV. Proinflammatory Cytokines IL-6 and TNF-a Increased Telomerase Activity through NF-?B/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017; 2017:5958429. PMID: 28676732.
      Citations: 26     Fields:    Translation:HumansCells
    40. Bhat K, Sarkissyan M, Wu Y, Vadgama JV. GROa overexpression drives cell migration and invasion in triple negative breast cancer cells. Oncol Rep. 2017 Jul; 38(1):21-30. PMID: 28560447.
      Citations: 11     Fields:    Translation:HumansCells
    41. Wang P, Solorzano W, Diaz T, Magyar CE, Henning SM, Vadgama JV. Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp. 2017 Jun; 13:1-11. PMID: 29062885.
      Citations:    
    42. Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim J, Nava M, Clayton S, Pietras R, Farias-Eisner R, Vadgama JV. A83-01 inhibits TGF-ß-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2017 Jun; 163(3):449-460. PMID: 28337662.
      Citations: 22     Fields:    Translation:HumansCells
    43. Chung SS, Adekoya D, Enenmoh I, Clarke O, Wang P, Sarkyssian M, Wu Y, Vadgama JV. Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells. Anticancer Res. 2017 02; 37(2):445-453. PMID: 28179289.
      Citations: 9     Fields:    Translation:HumansCells
    44. Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M, Elshimali Y, Kemp KT, Bhat K, Haro J, Sarkissyan M, Vadgama JV. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017 03 15; 77(6):1383-1394. PMID: 28115363.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    45. Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV. Lactate, a Neglected Factor for Diabetes and Cancer Interaction. Mediators Inflamm. 2016; 2016:6456018. PMID: 28077918.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    46. Gelfand R, Vernet D, Bruhn KW, Sarkissyan S, Heber D, Vadgama JV, Gonzalez-Cadavid NF. Long-term exposure of MCF-7 breast cancer cells to ethanol stimulates oncogenic features. Int J Oncol. 2017 Jan; 50(1):49-65. PMID: 27959387.
      Citations: 10     Fields:    Translation:HumansCells
    47. Chung SS, Oliva B, Dwabe S, Vadgama JV. Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol. 2016 Aug; 49(2):487-98. PMID: 27279256.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    48. Wang P, Henning SM, Magyar CE, Elshimali Y, Heber D, Vadgama JV. Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin Cancer Res. 2016 May 06; 35:73. PMID: 27151407.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    49. Gelfand R, Vernet D, Bruhn K, Vadgama J, Gonzalez-Cadavid NF. Long-term exposure of MCF-12A normal human breast epithelial cells to ethanol induces epithelial mesenchymal transition and oncogenic features. Int J Oncol. 2016 Jun; 48(6):2399-414. PMID: 27035792.
      Citations: 7     Fields:    Translation:HumansCells
    50. Wu Y, Liu Y, Dong Y, Vadgama J. Diabetes-associated dysregulated cytokines and cancer. Integr Cancer Sci Ther. 2016 Feb; 3(1):370-378. PMID: 29930868.
      Citations:    
    51. Wu Y, Sarkissyan M, Vadgama JV. Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016 Jan 26; 5(2). PMID: 26821054.
      Citations:    
    52. Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama JV. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PLoS One. 2015; 10(8):e0134948. PMID: 26258407.
      Citations: 6     Fields:    Translation:HumansCells
    53. Bazargan M, Lucas-Wright A, Jones L, Vargas R, Vadgama JV, Evers-Manly S, Maxwell AE. Understanding Perceived Benefit of Early Cancer Detection: Community-Partnered Research with African American Women in South Los Angeles. J Womens Health (Larchmt). 2015 Sep; 24(9):755-61. PMID: 26131760.
      Citations: 5     Fields:    Translation:Humans
    54. Wu Y, Sarkissyan M, Mcghee E, Lee S, Vadgama JV. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat. 2015 Jun; 151(3):529-39. PMID: 25975952.
      Citations: 22     Fields:    Translation:HumansCells
    55. Hamilton N, Márquez-Garbán D, Mah V, Fernando G, Elshimali Y, Garbán H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Biologic roles of estrogen receptor-ß and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015; 2015:925703. PMID: 25874233.
      Citations: 25     Fields:    Translation:HumansCells
    56. Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y, Vadgama JV. Slug contributes to cancer progression by direct regulation of ERa signaling pathway. Int J Oncol. 2015 Apr; 46(4):1461-72. PMID: 25652255.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    57. Wang P, Henning SM, Heber D, Vadgama JV. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015 Apr; 26(4):408-15. PMID: 25655047.
      Citations: 26     Fields:    Translation:HumansCells
    58. Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R. Estrogen Receptor-ß and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Crit Rev Oncog. 2015; 20(5-6):373-90. PMID: 27279236.
      Citations: 3     Fields:    Translation:Humans
    59. Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NF?B signaling. Anticancer Res. 2015 Jan; 35(1):39-46. PMID: 25550533.
      Citations: 76     Fields:    Translation:HumansCells
    60. Wu Y, Sarkissyan M, Vadgama JV. Epigenetics in breast and prostate cancer. Methods Mol Biol. 2015; 1238:425-66. PMID: 25421674.
      Citations: 32     Fields:    Translation:HumansAnimals
    61. Wang P, Phan T, Gordon D, Chung S, Henning SM, Vadgama JV. Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Mol Nutr Food Res. 2015 Feb; 59(2):250-61. PMID: 25380086.
      Citations: 13     Fields:    Translation:HumansCells
    62. Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv. 2014 Aug 05; 4(66):35242-35250. PMID: 25243063.
      Citations:    
    63. Sarkissyan S, Sarkissyan M, Wu Y, Cardenas J, Koeffler HP, Vadgama JV. IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One. 2014; 9(7):e103534. PMID: 25062088.
      Citations: 23     Fields:    Translation:AnimalsCells
    64. Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV. Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice. BMC Cancer. 2014 Apr 17; 14:266. PMID: 24742286.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    65. Sarkissyan M, Wu Y, Chen Z, Mishra DK, Sarkissyan S, Giannikopoulos I, Vadgama JV. Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer. 2014 May 01; 120(9):1387-93. PMID: 24510435.
      Citations: 18     Fields:    Translation:Humans
    66. Lucas-Wright A, Bazargan M, Jones L, Vadgama JV, Vargas R, Sarkissyan M, Smith J, Yazdanshenas H, Maxwell AE. Correlates of perceived risk of developing cancer among African-Americans in South Los Angeles. J Community Health. 2014 Feb; 39(1):173-80. PMID: 24026303.
      Citations: 10     Fields:    Translation:Humans
    67. Chung SS, Aroh C, Vadgama JV. Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One. 2013; 8(12):e83971. PMID: 24386318.
      Citations: 52     Fields:    Translation:HumansCells
    68. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014 Feb; 44(2):403-11. PMID: 24297508.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    69. Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS One. 2013; 8(10):e78259. PMID: 24167614.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    70. Wang P, Vadgama JV, Said JW, Magyar CE, Doan N, Heber D, Henning SM. Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J Nutr Biochem. 2014 Jan; 25(1):73-80. PMID: 24314868.
      Citations: 25     Fields:    Translation:AnimalsCells
    71. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013 Sep 13; 14(9):18925-58. PMID: 24065096.
      Citations: 91     Fields:    Translation:HumansCells
    72. Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6109-14. PMID: 23536305.
      Citations: 34     Fields:    Translation:HumansCells
    73. Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, Ong M, Heber D, Koeffler HP, Vadgama JV. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013; 8(3):e57967. PMID: 23554871.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    74. Jones L, Bazargan M, Lucas-Wright A, Vadgama JV, Vargas R, Smith J, Otoukesh S, Maxwell AE. Comparing perceived and test-based knowledge of cancer risk and prevention among Hispanic and African Americans: an example of community participatory research. Ethn Dis. 2013; 23(2):210-6. PMID: 23530303.
      Citations: 3     Fields:    Translation:Humans
    75. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/ß-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012 Dec; 10(12):1597-606. PMID: 23071104.
      Citations: 106     Fields:    Translation:HumansCells
    76. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012; 2(1):104-15. PMID: 22206049.
      Citations:    
    77. Sarkissyan M, Mishra DK, Wu Y, Shang X, Sarkissyan S, Vadgama JV. IGF gene polymorphisms and breast cancer in African-American and Hispanic women. Int J Oncol. 2011 Jun; 38(6):1663-73. PMID: 21455574.
      Citations: 7     Fields:    Translation:Humans
    78. Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, Vadgama J, Lyons KM, Koeffler HP. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 2011 Jun; 38(6):1741-7. PMID: 21455569.
      Citations: 36     Fields:    Translation:HumansCells
    79. Sarkissyan M, Wu Y, Vadgama JV. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer. 2011 Aug 15; 117(16):3814-23. PMID: 21305540.
      Citations: 15     Fields:    Translation:Humans
    80. Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said JW, Black KL, Koeffler HP. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer. 2010 Nov 15; 127(10):2257-67. PMID: 20162579.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    81. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 2010 Jul 01; 70(13):5475-85. PMID: 20551062.
      Citations: 27     Fields:    Translation:HumansCells
    82. Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010 Feb 04; 10:32. PMID: 20132554.
      Citations: 30     Fields:    Translation:HumansCells
    Vadgama's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (285)
    Explore
    _
    Co-Authors (42)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support